XBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Xenetic Biosciences Inc (XBIO) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While there are some positive indicators such as revenue growth and improved cost control, the company's financial performance shows significant losses and declining EPS. Additionally, technical indicators are neutral, and there are no strong trading signals or significant catalysts to suggest immediate upside potential. A hold position is recommended until stronger signals or catalysts emerge.
The MACD histogram is positive at 0.0737, indicating slight bullish momentum, but it is contracting. RSI is neutral at 62.179, and moving averages are converging, showing no clear trend. Key support is at 2.334, and resistance is at 3.319, with the stock currently trading at 2.94 in pre-market. Overall, the technical indicators suggest a neutral trend.
Royalty revenue from Takeda Pharmaceuticals increased by 19%, indicating potential for global market expansion. Research and development expenses decreased, reflecting improved cost control. Revenue increased by 18.11% YoY in Q4 2025.
The company reported a net loss of $2.7 million for FY 2025, reflecting ongoing challenges in profitability.
In Q4 2025, revenue increased by 18.11% YoY to $766,296, but net income dropped by 45.09% YoY to -$579,076. EPS declined significantly by 60.29% YoY to -0.27. Gross margin remained steady at 100%. While revenue growth is positive, the company is still struggling with profitability.
No analyst rating or price target changes were provided. Hedge funds and insiders are neutral, with no significant trading trends in the last quarter or month.
